Published online Jul 6, 2017. doi: 10.5527/wjn.v6.i4.176
Peer-review started: February 14, 2017
First decision: April 14, 2017
Revised: April 21, 2017
Accepted: May 3, 2017
Article in press: May 6, 2017
Published online: July 6, 2017
Processing time: 136 Days and 4 Hours
Our meta-analysis published in 2010 provided evidence that low levels of serum albumin (hypoalbuminemia) are a significant independent predictor of acute kidney injury (AKI) and death following AKI. Since then, a large volume of additional data from observational clinical studies has been published further evaluating the relationship between serum albumin and AKI occurrence. This is an updated review of the literature to re-evaluate the hypothesis that hypoalbuminemia is independently associated with increased AKI risk. Eligible studies published from September 2009 to December 2016 were sought in PubMed (MEDLINE) and forty-three were retained, the great majority being retrospective observational cohort studies. These included a total of about 68000 subjects across a diverse range of settings, predominantly cardiac surgery and acute coronary interventions, infectious diseases, transplant surgery, and cancer. Appraisal of this latest data set served to conclusively corroborate and confirm our earlier hypothesis that lower serum albumin is an independent predictor both of AKI and death after AKI, across a range of clinical scenarios. The body of evidence indicates that hypoalbuminemia may causally contribute to development of AKI. Furthermore, administration of human albumin solution has the potential to prevent AKI; a randomized, controlled study provides evidence that correcting hypoalbuminemia may be renal-protective. Therefore, measurement of serum albumin to diagnose hypoalbuminemia may help identify high-risk patients who may benefit from treatment with exogenous human albumin. Multi-center, prospective, randomized, interventional studies are warranted, along with basic research to define the mechanisms through which albumin affords nephroprotection.
Core tip: The relationship between hypoalbuminemia and acute kidney injury (AKI)-related morbidity/mortality is now confirmed. This association is consistently evident in a wealth of observational studies conducted across a wide range of clinical settings, and suggests a causal link. Prospective studies adequately powered to assess severe AKI, mortality and causality are needed, as is evaluation of the trigger and appropriate target serum levels and albumin dose necessary to confer renal protection. Basic research is also warranted to define the mechanisms through which albumin affords nephroprotection. Serum albumin should be measured to identify patients with increased AKI risk who may benefit from treatment correcting underlying hypoalbuminemia.